Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2013 June
  • Home
  • Archive for June, 2013

BIOSORTIA PHARMACEUTICALS INVITED TO PRESENT NATIONAL BUSINESS INNOVATION FORUM

  • June 26 2013

Dublin, OH (June 2013) – Dublin, Ohio-based Biosortia Pharmaceuticals has accepted the offer to present at the Innovation Forum in New York City on June 27th at the Yale Club. Biosortia, a premier, aquatic natural products company, is building a library of potent, active, and patented compounds with a primary focus on drug discovery in cancer,

Continue Reading

BIOSORTIA LAUNCHES INFECTIOUS DISEASE DRUG DISCOVERY TRIAL

  • June 11 2013

Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of

Continue Reading

RSS Industry News

  • Practical lessons from microbiome citizen-science projects May 4 2026
  • Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding May 4 2026
  • A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis April 30 2026
  • Navigating the translational labyrinth of the gut microbiota April 29 2026
  • Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial April 27 2026
  • Community context reshapes microbial proteomes and reduces functional overlap April 24 2026
  • Author Correction: Commensal yeast promotes Salmonella Typhimurium virulence April 24 2026
  • The network structure of cross-feeding impacts microbial community diversity under growth-inhibiting stresses April 23 2026
  • Ketogenic diet exacerbates DSS-induced colitis through a β-hydroxybutyrate-Thomasclavelia spiroformis-γδ17 T cell axis in mice April 23 2026
  • Human milk oligosaccharide mediates mutualism between Escherichia coli and Bifidobacterium bifidum April 22 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism
  • Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
  • Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.